Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Hepatitis b Virus, Hepatitis B
Interventions: HepB mAb19, Sterile Saline; Biological · Other
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: New York, New York

Conditions: Celiac Disease
Interventions: larazotide acetate, placebo, 900 mg gluten; Drug · Dietary Supplement
Lead sponsor: 9 Meters Biopharma, Inc.; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 17
States / cities: Scottsdale, Arizona • Colorado Springs, Colorado • Chicago, Illinois + 14 more

Conditions: Meniere's Disease
Interventions: OTO-104 (steroid) 3 mg, Placebo, OTO-104 (steroid) 12 mg; Drug
Lead sponsor: Otonomy, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 15
States / cities: Los Angeles, California • San Diego, California • Colorado Springs, Colorado + 12 more

Conditions: Pruritus, Atopic Dermatitis
Interventions: SRD174 Cream, vehicle cream; Drug · Other
Lead sponsor: Serentis Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 13
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Oceanside, California + 10 more

Conditions: Psoriatic Arthritis
Interventions: Apremilast 30 mg, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 24
States / cities: Birmingham, Alabama • Palm Desert, California • Brandon, Florida + 20 more

Conditions: Diabetic Foot Ulcers
Interventions: MEBO Wound Ointment, Standard of Care (sterile saline moistened gauze); Drug · Procedure
Lead sponsor: Skingenix, Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: New Haven, Connecticut • Boston, Massachusetts

Conditions: Fragile X Syndrome
Interventions: AZD7325 (High-Dose), AZD7325 (Low-Dose), Placebo oral capsule; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 50 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Oral Mucositis, Head and Neck Cancer
Interventions: EN3285, Placebo, Standard of care; Drug · Other
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Louisville, Kentucky • Houston, Texas

Conditions: Pemphigus Vulgaris
Interventions: Enbrel (Etanercept); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Musculoskeletal Complications, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: naproxen, placebo; Drug · Other
Lead sponsor: Gary Morrow; Other
Eligibility: 18 Years to 120 Years
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 16
States / cities: Honolulu, Hawaii • Decatur, Illinois • Evanston, Illinois + 13 more

Conditions: Soft Tissue Infections
Interventions: Standard care, beta-lactam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 8
States / cities: Birmingham, Alabama • Mobile, Alabama • Melbourne, Florida + 4 more

Conditions: Colitis, Ulcerative
Interventions: BMS-986165, Placebo Comparator; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: San Diego, California • Arlington Heights, Illinois • Shreveport, Louisiana + 7 more

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 48
States / cities: Anchorage, Alaska • La Jolla, California • Los Angeles, California + 39 more

Conditions: Giant Cell Arteritis
Interventions: mavrilimumab, placebo, prednisone; Combination Product · Drug
Lead sponsor: Kiniksa Pharmaceuticals, Ltd.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: Sarasota, Florida • Tampa, Florida • Atlanta, Georgia + 5 more

Conditions: Neuropathic Pain
Interventions: SAR292833, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 28
States / cities: Tucson, Arizona • Garden Grove, California • Newport Beach, California + 24 more

Conditions: Breast Neoplasms, Neoplasm Metastasis
Interventions: Growing Resiliency And CouragE with Cancer™ (GRACE); Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Migraine
Interventions: Xeomin, Placebo; Drug
Lead sponsor: Merz Therapeutics GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 808 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 48
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 42 more

Conditions: Colon Polyps
Interventions: Educational Training; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Healthy
Interventions: BMS-986166, Placebo matching BMS-986166; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hair Thinning
Interventions: Active Comparator- Xtressé™ Supplement and Serum, Placebo Comparator- Placebo Supplement and Serum; Dietary Supplement
Lead sponsor: The Center for Clinical and Cosmetic Research; Other
Eligibility: 28 Years to 65 Years · Female only
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Birmingham, Alabama • Aventura, Florida

Conditions: COPD
Interventions: Formoterol Fumarate, Tiotropium Bromide; Drug
Lead sponsor: Dey; Industry
Eligibility: 40 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 17
States / cities: Phoenix, Arizona • Los Angeles, California • Sepulveda, California + 14 more

Conditions: Crohn's Disease
Interventions: Double-blind (DB) adalimumab placebo, DB adalimumab 40 mg eow, DB adalimumab 40 mg ew, OL adalimumab 40 mg; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 43
States / cities: Berkeley, California • Long Beach, California • San Diego, California + 36 more

Conditions: Physical Activity
Interventions: Activity monitor, Activity device; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years to 45 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus
Interventions: Pharmacist Management, Usual care; Other
Lead sponsor: Advantage Health Physician Network; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Search by objective public record fields.

HepB mAb19 in Individuals With Chronic Hepatitis B Infection

Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease

OTO-104 for Meniere's Disease

Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus

Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis

A Clinical Study of the Safety and Efficacy of MEBO® Wound Ointment in Subjects With Diabetic Foot Ulcers (Pilot)

An Initial Study of AZD7325 in Adults With Fragile X Syndrome

EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer

Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris

Prevention of Pegfilgrastim-Induced Bone Pain (PIBP)

A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections

A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

KPL-301 for Subjects With Giant Cell Arteritis

Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain

A Trial to Strengthen Existential Resiliency Among Women With Metastatic Breast Cancer

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

A Prospective Trial of an Endoscopic Quality Improvement Project

A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

Evaluating the Combined Use of Supplement and Serum in Promoting Hair Growth in Women With Self-perceived Thinning Hair

A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD

Remission in Subjects With Crohn's Disease, 1 Year Phase

Be Fit in Residency: a Randomized Controlled Trial of an Activity Device Among Medicine Residents

Pharmacists Management of Diabetes